Stock Events

Stock Events

Kinnate Biopharma 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap628.35M
Array BioPharma (acquired by Pfizer) specializes in the development of targeted cancer therapy drugs, competing in the same space as Kinnate.
AMGEN
AMGN
Mkt Cap217.9B
Amgen has a broad portfolio including targeted cancer therapies, making it a competitor in the precision oncology field.
Novartis
NVS
Mkt Cap268B
Novartis has a strong emphasis on oncology and precision medicine, making it a direct competitor in the targeted therapy market.
Merck
MRK
Mkt Cap356.01B
Merck's focus on oncology, especially with its leading immunotherapy drug Keytruda, places it in competition with companies like Kinnate focusing on cancer.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb, with its range of cancer treatments and focus on innovative therapies, competes in the oncology space.
Pfizer
PFE
Mkt Cap158.45B
Pfizer's acquisition of Array BioPharma and its ongoing development of cancer therapies make it a competitor in the targeted oncology market.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, known for its work in antiviral drugs, has expanded into oncology, competing with Kinnate's cancer focus.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca has a strong pipeline in oncology, including targeted therapies, competing with Kinnate's focus on precision medicine.

About

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Show More
CEO
Nima Farzan
Employees
84
Country
United States
ISIN
US49705R1059
WKN
000A2QHVT

Listings

STU
DE
6KB.STU

0 Comments

Share your thoughts

FAQs

What is Kinnate Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Kinnate Biopharma stocks are traded under the ticker 6KB.STU.
How many employees does Kinnate Biopharma have?▼
As of November 2, 2026, the company has 84 employees.
In which sector is Kinnate Biopharma located?▼
Kinnate Biopharma operates in the Manufacturing sector.
When did Kinnate Biopharma complete a stock split?▼
Kinnate Biopharma has not had any recent stock splits.
Where is Kinnate Biopharma headquartered?▼
Kinnate Biopharma is headquartered in San Francisco, United States.